Denali Therapeutics Inc (NASDAQ:DNLI) Shares Acquired by Russell Investments Group Ltd.

Russell Investments Group Ltd. grew its holdings in Denali Therapeutics Inc (NASDAQ:DNLI) by 37.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,540 shares of the company’s stock after buying an additional 9,650 shares during the quarter. Russell Investments Group Ltd.’s holdings in Denali Therapeutics were worth $736,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of DNLI. SG Americas Securities LLC acquired a new stake in shares of Denali Therapeutics in the 1st quarter valued at approximately $208,000. Xact Kapitalforvaltning AB acquired a new stake in shares of Denali Therapeutics in the 2nd quarter valued at approximately $210,000. Acadian Asset Management LLC lifted its holdings in shares of Denali Therapeutics by 136.7% in the 2nd quarter. Acadian Asset Management LLC now owns 11,650 shares of the company’s stock valued at $241,000 after buying an additional 6,728 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Denali Therapeutics by 19.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 13,170 shares of the company’s stock valued at $271,000 after buying an additional 2,101 shares during the period. Finally, Public Employees Retirement Association of Colorado acquired a new stake in shares of Denali Therapeutics in the 2nd quarter valued at approximately $291,000. 73.91% of the stock is owned by institutional investors and hedge funds.

In other news, COO Alexander O. Schuth sold 7,500 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $18.16, for a total value of $136,200.00. Also, insider Ryan J. Watts sold 18,333 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $20.76, for a total value of $380,593.08. The disclosure for this sale can be found here. Over the last three months, insiders sold 66,914 shares of company stock valued at $1,319,930. Insiders own 21.20% of the company’s stock.



Several research firms have recently commented on DNLI. Zacks Investment Research cut Denali Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 7th. BTIG Research began coverage on Denali Therapeutics in a report on Friday, August 9th. They set a “buy” rating and a $30.00 price objective for the company. ValuEngine raised Denali Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 4th. Morgan Stanley set a $32.00 price objective on Denali Therapeutics and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Denali Therapeutics in a report on Thursday, August 8th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $28.43.

DNLI stock traded down $0.52 during midday trading on Tuesday, hitting $17.26. 9,211 shares of the stock were exchanged, compared to its average volume of 285,702. The stock’s 50-day moving average price is $18.40 and its 200-day moving average price is $21.06. The stock has a market cap of $1.73 billion, a price-to-earnings ratio of -44.26 and a beta of 2.21. Denali Therapeutics Inc has a fifty-two week low of $13.78 and a fifty-two week high of $28.86. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.66 and a current ratio of 10.65.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.15). The firm had revenue of $4.20 million for the quarter, compared to analyst estimates of $4.52 million. Denali Therapeutics had a negative return on equity of 11.03% and a negative net margin of 40.78%. Research analysts anticipate that Denali Therapeutics Inc will post -2.02 EPS for the current year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Featured Story: Does a trade war provide a risk to the global economy?

Institutional Ownership by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.